Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumor Grade 2”

66 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 66 results

Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH 40
Very early researchActive Not RecruitingNCT05111509
What this trial is testing

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Who this might be right for
Neuroendocrine Tumor Grade 2Neuroendocrine Tumor Grade 1
Yusuf Menda 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Early research (Phase 1)Looking for participantsNCT07114939
What this trial is testing

FTT PET/CT in Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Carcinoma MetastaticPancreatic Tumors
Abramson Cancer Center at Penn Medicine 12
Testing effectiveness (Phase 2)Study completedNCT02939651
What this trial is testing

Pembrolizumab in Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Looking for participantsNCT07016230
What this trial is testing

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Who this might be right for
Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
Gustave Roussy, Cancer Campus, Grand Paris
Testing effectiveness (Phase 2)Ended earlyNCT03670030
What this trial is testing

TestABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

Who this might be right for
Neuroendocrine Tumors
Robert Ramirez 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727
What this trial is testing

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Who this might be right for
Small-Cell Lung CancerNeuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232
Not applicableLooking for participantsNCT04464122
What this trial is testing

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1+2 more
University of Roma La Sapienza 60
Very early researchActive Not RecruitingNCT06148636
What this trial is testing

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor of the LungNeuroendocrine Tumor Grade 1+2 more
David Bushnell 24
Early research (Phase 1)Active Not RecruitingNCT02088645
What this trial is testing

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

Who this might be right for
Thyroid Cancer, MedullaryNeuroendocrine Tumor of the Lung Grade 1 and 2Neuroendocrine Tumor of the Thymus Grade 1 and 2+1 more
University Hospital, Basel, Switzerland 24
Large-scale testing (Phase 3)Study completedNCT04852679
What this trial is testing

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 43
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT04010357
What this trial is testing

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Who this might be right for
Small-cell Lung CancerLarge Cell Neuroendocrine Carcinoma of the LungExtrapulmonary Small Cell Carcinoma
Case Comprehensive Cancer Center 14
Testing effectiveness (Phase 2)Ended earlyNCT01702896
What this trial is testing

Interleukin-2 in Metastatic Melanoma

Who this might be right for
Melanoma Metastatic
Western Regional Medical Center 8
Early research (Phase 1)Ended earlyNCT01088763
What this trial is testing

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Who this might be right for
Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germinoma+43 more
National Cancer Institute (NCI) 129
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774
What this trial is testing

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Study completedNCT01125046
What this trial is testing

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Who this might be right for
Acoustic SchwannomaAdult Anaplastic MeningiomaAdult Ependymoma+7 more
Northwestern University 50
Early research (Phase 1)Ended earlyNCT01769222
What this trial is testing

Ipilimumab and Local Radiation for Selected Solid Tumors

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+31 more
Stanford University 3
Load More Results
40